trimebutin | Neobutin Retard sustained release tablets 300 mg 20 pcs
Special Price
$21.34
Regular Price
$29.00
In stock
SKU
BID689088
Release form
Long-acting film-coated tablets, 300 mg.
Long-acting film-coated tablets, 300 mg.
Release form
Long-acting film-coated tablets, 300 mg.
Packaging
5.10 tablets in blister packs of PVC film and varnished aluminum foil.
On 1, 2, 3, 4 or 6 blister strip packagings together with the application instruction are placed in a cardboard pack.
Pharmacological action of
Pharmacotherapeutic group:
antispasmodic
ATX code: [A03AA05]
Pharmacological properties of
Pharmacodynamics
Trimebutin, acting on the enkephalinergic system, is its pericenteric system. Acting on peripheral -, - and - receptors, including those located directly on smooth muscle throughout the gastrointestinal tract (GIT), it regulates motility without affecting the central nervous system.
Thus, trimebutin restores the normal physiological activity of the intestinal muscles in various diseases of the gastrointestinal tract associated with impaired motor skills.
Normalizing visceral sensitivity, trimebutin provides an analgesic effect in abdominal pain.
Pharmacokinetics
Absorption and distribution.
After oral administration, trimebutin is rapidly absorbed from the digestive tract. Distribution volume (Vd) - 88 l. The degree of binding to plasma proteins is low - about 5%. Trimebutin to a small extent penetrates the placental barrier.
Metabolism and excretion.
Trimebutin is biotransformed in the liver and excreted in the urine mainly in the form of metabolites.
Indications
Symptomatic treatment of pain and discomfort in the abdomen, cramping, bloating (flatulence), intestinal motor disorders with a change in stool frequency (diarrhea, constipation or their alternation), changes in stool consistency associated with irritable bowel syndrome.
Postoperative paralytic intestinal obstruction.
Contraindications
Hypersensitivity to the components that make up the drug.
Children under 12 years old.
Pregnancy.
Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
Use during pregnancy and lactation
In experimental studies, no data were found on teratogenicity and embryotoxicity of trimebutin. However, due to the lack of necessary clinical data, the use of trimebutin during pregnancy is contraindicated.
Breastfeeding period. It is not recommended to use trimebutin during breastfeeding, due to the lack of reliable clinical data confirming the safety of trimebutin during this period.
If you need to use trimebutin during breastfeeding, breastfeeding should be discontinued.
Special instructions
Effect on the ability to drive vehicles and mechanisms
The drug NeobutinВ® retard does not have a sedative effect, does not affect the speed of the psychomotor reaction and can be used in persons of various professions, including those requiring increased attention and coordination of movements.
However, given the possible side effects that may affect these abilities (dizziness and others), you should be careful when driving and engaging in other potentially dangerous activities.
Composition
Active ingredient:
trimebutine maleate 300.0 mg
Excipients:
Core tablets:
lactose monohydrate 180.0 mg,
tartaric acid 120.0 mg,
hypromellose 12.0 mg, 20.0 mg 0 mg,
silicon dioxide colloidal 7.5 mg,
magnesium stearate 7.5 mg.
Shell:
hypromellose 6.82 mg,
talcum 1.35 mg,
Opasprey white M-1-7111 [titanium dioxide 30.0%, ethanol denatured (methylated alcohol) 10.0%, hypromellose-2910 3.0 %, water 57.0%] 2.25 mg,
silicon defoamer qs
Description:
Tablets, film-coated, white or almost white, biconvex, oblong in shape with rounded ends. In a cross section, the core is white or almost white. In the production of ԓamil Farm. Co., Ltd. Ԭ Republic of Korea, one side of
embossed tablets is additionally labeled withӠSR Լbr>
Dosage and administration
Inside, before meals.
Adults and children over 12 years of age, 300 mg 2 times a day.
Maximum daily dose of 600 mg.
Side effects of the
From the digestive system: dry mouth, unpleasant taste, diarrhea, dyspepsia, epigastric pain, nausea, constipation.
From the nervous system: drowsiness, fatigue, dizziness, headache, anxiety, weakness, feeling of heat or cold. Allergic reactions: skin allergic reactions.
Other: menstrual irregularities, painful enlargement of the mammary glands, urinary retention.
Drug Interactions
Drug Interactions Neobutin® Retard not described. Special instructions
The recommended course of treatment of irritable bowel syndrome in the acute period of 600 mg per day for 4 weeks.
Overdose
No trimebutin overdose has been reported to date.
Storage Conditions
In a dark place at a temperature not exceeding 25 РC.
Keep out of the reach and sight of children.
Shelf life
3 years. Do not use after the expiration date indicated on the package.
Deystvuyushtee substance
trimebutine
Dosage form
prolong tablets.
Possible product names
Neobutin retard sustained release tablets 300 mg 20 pcs.
Long-acting film-coated tablets, 300 mg.
Packaging
5.10 tablets in blister packs of PVC film and varnished aluminum foil.
On 1, 2, 3, 4 or 6 blister strip packagings together with the application instruction are placed in a cardboard pack.
Pharmacological action of
Pharmacotherapeutic group:
antispasmodic
ATX code: [A03AA05]
Pharmacological properties of
Pharmacodynamics
Trimebutin, acting on the enkephalinergic system, is its pericenteric system. Acting on peripheral -, - and - receptors, including those located directly on smooth muscle throughout the gastrointestinal tract (GIT), it regulates motility without affecting the central nervous system.
Thus, trimebutin restores the normal physiological activity of the intestinal muscles in various diseases of the gastrointestinal tract associated with impaired motor skills.
Normalizing visceral sensitivity, trimebutin provides an analgesic effect in abdominal pain.
Pharmacokinetics
Absorption and distribution.
After oral administration, trimebutin is rapidly absorbed from the digestive tract. Distribution volume (Vd) - 88 l. The degree of binding to plasma proteins is low - about 5%. Trimebutin to a small extent penetrates the placental barrier.
Metabolism and excretion.
Trimebutin is biotransformed in the liver and excreted in the urine mainly in the form of metabolites.
Indications
Symptomatic treatment of pain and discomfort in the abdomen, cramping, bloating (flatulence), intestinal motor disorders with a change in stool frequency (diarrhea, constipation or their alternation), changes in stool consistency associated with irritable bowel syndrome.
Postoperative paralytic intestinal obstruction.
Contraindications
Hypersensitivity to the components that make up the drug.
Children under 12 years old.
Pregnancy.
Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
Use during pregnancy and lactation
In experimental studies, no data were found on teratogenicity and embryotoxicity of trimebutin. However, due to the lack of necessary clinical data, the use of trimebutin during pregnancy is contraindicated.
Breastfeeding period. It is not recommended to use trimebutin during breastfeeding, due to the lack of reliable clinical data confirming the safety of trimebutin during this period.
If you need to use trimebutin during breastfeeding, breastfeeding should be discontinued.
Special instructions
Effect on the ability to drive vehicles and mechanisms
The drug NeobutinВ® retard does not have a sedative effect, does not affect the speed of the psychomotor reaction and can be used in persons of various professions, including those requiring increased attention and coordination of movements.
However, given the possible side effects that may affect these abilities (dizziness and others), you should be careful when driving and engaging in other potentially dangerous activities.
Composition
Active ingredient:
trimebutine maleate 300.0 mg
Excipients:
Core tablets:
lactose monohydrate 180.0 mg,
tartaric acid 120.0 mg,
hypromellose 12.0 mg, 20.0 mg 0 mg,
silicon dioxide colloidal 7.5 mg,
magnesium stearate 7.5 mg.
Shell:
hypromellose 6.82 mg,
talcum 1.35 mg,
Opasprey white M-1-7111 [titanium dioxide 30.0%, ethanol denatured (methylated alcohol) 10.0%, hypromellose-2910 3.0 %, water 57.0%] 2.25 mg,
silicon defoamer qs
Description:
Tablets, film-coated, white or almost white, biconvex, oblong in shape with rounded ends. In a cross section, the core is white or almost white. In the production of ԓamil Farm. Co., Ltd. Ԭ Republic of Korea, one side of
embossed tablets is additionally labeled withӠSR Լbr>
Dosage and administration
Inside, before meals.
Adults and children over 12 years of age, 300 mg 2 times a day.
Maximum daily dose of 600 mg.
Side effects of the
From the digestive system: dry mouth, unpleasant taste, diarrhea, dyspepsia, epigastric pain, nausea, constipation.
From the nervous system: drowsiness, fatigue, dizziness, headache, anxiety, weakness, feeling of heat or cold. Allergic reactions: skin allergic reactions.
Other: menstrual irregularities, painful enlargement of the mammary glands, urinary retention.
Drug Interactions
Drug Interactions Neobutin® Retard not described. Special instructions
The recommended course of treatment of irritable bowel syndrome in the acute period of 600 mg per day for 4 weeks.
Overdose
No trimebutin overdose has been reported to date.
Storage Conditions
In a dark place at a temperature not exceeding 25 РC.
Keep out of the reach and sight of children.
Shelf life
3 years. Do not use after the expiration date indicated on the package.
Deystvuyushtee substance
trimebutine
Dosage form
prolong tablets.
Possible product names
Neobutin retard sustained release tablets 300 mg 20 pcs.
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review